[O-34] Oral Session 34
Clinical trial and Regenerative medicine 2 E

[O-34-8] Eculizumab for generalized myasthenia gravis: interim analysis of post-marketing surveillance

^○Hiroyuki Murai¹, Shigeaki Suzuki², Miki Hasebe³, Yuji Fukamizu³, Ema Rodrigues⁴, Kimiaki Utsugisawa⁵ (1.International University of Health and Welfare, Japan, 2.Keio University School of Medicine, Tokyo, 3.Alexion Pharma GK, 4.Alexion Pharmaceuticals, Inc, 5.General Hanamaki Hospital)